Kathryn Falberg

Ms. Falberg currently serves as a member of the Board and Chair of the Audit Committee for several companies in the life sciences and technology industries, including Arcus Biosciences, UroGen Pharma, Tricida and The Trade Desk. Throughout her career, she has held several Chief Financial Officer roles in the biotechnology and technology industries, including for Applied Magnetics, Amgen and, most recently, Jazz Pharmaceuticals. Previously, Ms. Falberg served on the Board of Medivation until its acquisition by Pfizer, as well as other Boards including Aimmune Therapeutics, Halozyme Therapeutics, BioMarin Pharmaceutical and Human Genome Sciences. Ms. Falberg received a B.A. in economics and an M.B.A. from the University of California, Los Angeles.